• Препараты для потенции
• Визарсин 100 12

Визарсин® 100 мг инструкция по применению, показания.

Viagra Kaboom Action Strips Erotil Revatio Vizarsin (potency)Falsigra Sildenafil citrate Activil Silden Sildenafil Sildenafil Ranbaxy Sildenafil Teva Xex Sildenafil Pfizer Defil Libigran Lovex Sildenafil Sandoz Adagrin Elonza The information provided in Name of the medicinal product of Визарсин is based on data of another medicine with exactly the same composition as the Визарсин. Be careful and be sure to specify the information on the section Name of the medicinal product in the instructions to the drug Визарсин directly from the package or from the pharmacist at the pharmacy. The information provided in Qualitative and quantitative composition of Визарсин is based on data of another medicine with exactly the same composition as the Визарсин. Be careful and be sure to specify the information on the section Qualitative and quantitative composition in the instructions to the drug Визарсин directly from the package or from the pharmacist at the pharmacy.

Визарсин таблетки покрытые пленочной оболочкой 100мг №12"визарсин таблетки покрытые пленочной оболочкой 100мг №12

The information provided in Pharmaceutical form of Визарсин is based on data of another medicine with exactly the same composition as the Визарсин. Be careful and be sure to specify the information on the section Pharmaceutical form in the instructions to the drug Визарсин directly from the package or from the pharmacist at the pharmacy. The information provided in Therapeutic indications of Визарсин is based on data of another medicine with exactly the same composition as the Визарсин.

Be careful and be sure to specify the information on the section Therapeutic indications in the instructions to the drug Визарсин directly from the package or from the pharmacist at the pharmacy. The information provided in Dosage (Posology) and method of administration of Визарсин is based on data of another medicine with exactly the same composition as the Визарсин. Be careful and be sure to specify the information on the section Dosage (Posology) and method of administration in the instructions to the drug Визарсин directly from the package or from the pharmacist at the pharmacy.

In case of clinical deterioration in spite of Визарсин treatment, alternative therapies should be considered. Physicians should advise patients who forget to take Визарсин to take a dose as soon as possible and then continue with the normal dose. Визарсин is contraindicated in patients with severe hepatic impairment (Child-Pugh class C),. Limited data suggest that the abrupt discontinuation of Визарсин is not associated with rebound worsening of pulmonary arterial hypertension. Визарсин powder for oral suspension is for oral use only.

Визарсин — эффективность препарата, описание и состав"› drugs › 467b84c1-f24f-4253-9f24-e25beВизарсин — эффективность препарата, описание и состав

The information provided in Contraindications of Визарсин is based on data of another medicine with exactly the same composition as the Визарсин. Be careful and be sure to specify the information on the section Contraindications in the instructions to the drug Визарсин directly from the package or from the pharmacist at the pharmacy. The safety of sildenafil has not been studied in the following sub-groups of patients and its use is therefore contraindicated: Severe hepatic impairment, Recent history of stroke or myocardial infarction, Severe hypotension (blood pressure The information provided in Special warnings and precautions for use of Визарсин is based on data of another medicine with exactly the same composition as the Визарсин.

Be careful and be sure to specify the information on the section Special warnings and precautions for use in the instructions to the drug Визарсин directly from the package or from the pharmacist at the pharmacy. The efficacy of Визарсин has not been established in patients with severe pulmonary arterial hypertension (functional class IV).   In a clinical study events of vaso-occlusive crises requiring hospitalisation were reported more commonly by patients receiving Визарсин than those receiving placebo leading to the premature termination of this study.  

The information provided in Effects on ability to drive and use machines of Визарсин is based on data of another medicine with exactly the same composition as the Визарсин. Be careful and be sure to specify the information on the section Effects on ability to drive and use machines in the instructions to the drug Визарсин directly from the package or from the pharmacist at the pharmacy.

Визарсин has moderate influence on the ability to drive and use machines. As dizziness and altered vision were reported in clinical trials with sildenafil, patients should be aware of how they might be affected by Визарсин, before driving or using machines. The information provided in Undesirable effects of Визарсин is based on data of another medicine with exactly the same composition as the Визарсин.

Визарсин Ку-таб таблетки диспергируемые в полости рта 100мг №12"Визарсин Ку-таб таблетки диспергируемые в полости рта 100мг №12

Be careful and be sure to specify the information on the section Undesirable effects in the instructions to the drug Визарсин directly from the package or from the pharmacist at the pharmacy. In the pivotal placebo-controlled study of Визарсин in pulmonary arterial hypertension, a total of 207 patients were randomized to and treated with 20 mg, 40 mg, or 80 mg TID doses of Визарсин and 70 patients were randomized to placebo. Doses up to 80 mg three times a day (4 times the recommended dose of 20 mg three times a day) were administered and after 3 years 87 % of 183 patients on study treatment were receiving Визарсин 80 mg TID. In a placebo-controlled study of Визарсин as an adjunct to intravenous epoprostenol in pulmonary arterial hypertension, a total of 134 patients were treated with Визарсин (in a fixed titration starting from 20 mg, to 40 mg and then 80 mg, three times a day as tolerated) and epoprostenol, and 131 patients were treated with placebo and epoprostenol. Doses up to 80 mg TID were administered and after 3 years 68 % of 133 patients on study treatment were receiving Визарсин 80 mg TID. The most commonly reported adverse reactions that occurred (greater or equal to 10 %) on Визарсин compared to placebo were headache, flushing, dyspepsia, diarrhoea and pain in extremity. In the placebo-controlled study of Визарсин in patients 1 to 17 years of age with pulmonary arterial hypertension, a total of 174 patients were treated three times a day with either low (10 mg in patients 45 kg) regimens of Визарсин and 60 were treated with placebo.

The information provided in Overdose of Визарсин is based on data of another medicine with exactly the same composition as the Визарсин. Be careful and be sure to specify the information on the section Overdose in the instructions to the drug Визарсин directly from the package or from the pharmacist at the pharmacy.